Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
PhD position in commercial environment: cancer immunotherapy drug screening in 3D (3DPD)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Netherlands
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 134625.0
EU funding (EUR): 134625.0
Participants: 1
Project status: CLOSED

OcellO B.V., a Dutch SME, is recruiting an Immuno-Oncology Innovation Associate to support the diversification of its portfolio of innovative services. OcellO is a contract research organization (CRO) that delivers supreme in vitro screening tools for drug developers. The SME has a number of high-throughput screening tools on the market, all of which are based on its proprietary 3D cell culture technique with concomitant imaging and analyses tools. Currently, OcellO is growing so-called ‘organoids’ composed of a single cell type. The different screening tools it now has on the market each make use of a single cell type of different origin. Strengthened by the needs expressed by the market, OcellO wants to expand its portfolio with the delivery of 3D cultures based on two or more different cell types combined in one organoid. The primary focus for this project is on combining cancer cells with cells from the immune system, to support the development of immuno-modulating cancer drugs – a highly promising field of anti-cancer drug development. There is a high unmet need for affordable and meaningful screening technologies for the selection of the most promising drugs for clinical development from a vast number of promising compounds designed for stimulating our immune system to eradicate cancer cells. None of the screening tools currently available can deliver on the needs of the industry. For the development of its first screening platform based on the co-culture of cells in 3D, OcellO is eager to hire a post-doc level, established researcher (R3). The Immuno-Oncology Innovation Associate has a PhD in immunology and experience in oncology. (S)he has affinity with cell biology, fluorescence imaging, and with exploitation of technology. In the competitive Dutch employment environment, it is hard for OcellO to compete for the top researchers. With EU support, OcellO can target a larger market and offer a truly competitive package of remuneration and fringe benefits.

Keywords: 3d culture,in vitro tests,cancer immunotherapy,compound screening,drug development,high,content screening,high throughput assays,post doc,vacancy,established researcher
Estonian Key Account Management Services 2020-2021 (EST-KAM20-21)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Specific Grant agreement
Countries involved: Estonia,Estonia
Call: H2020 ENTREPRISE EUROPE NETWORK SGA4 2020-2021 (H2020-EEN-SGA4-2020-2021, 2019)
Start date: 2020-01-01
End date: 2021-12-31
Duration (months): 24.0
Total project cost (EUR): 164150.0
EU funding (EUR): 164150.0
Participants: 5
Project status: CLOSED

The objective of the project is to enhance the innovation management capacity of Estonian SMEs. The action is aimed at two kinds of SMEs - beneficiaries of the EIC pilot and SMEs with significant innovation activities and a high potential for internationalisation. For beneficiaries of the EIC pilot, the service package (the Key Account Management service) consists of identifying weaknesses in the innovation capacities of the beneficiary; identifying suitable coaches (based on the assessment in the first step) to address the identified weaknesses and moderating the coach-client relationship; and accompanying the beneficiary through the EIC pilot project. The service packages outside the scope of the SME Instrument (the “Enhancing the innovation management capacity of SME's” service) consist of carrying out a diagnostic audit of the selected SMEs; and developing and implementing a tailored action plan to improve the SME’s capacity to manage innovation processes. Within the current action, the consortium aims to provide the service packages to 50 Estonian SMEs.

Keywords: innovation management capacity,eic pilot,eimc
Innovative tools to detect Glioblastoma (GBM) exosomes (Gl.EXO)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Society and Enterprise panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Netherlands
Call: Individual Fellowships (H2020-MSCA-IF-2019, 2019)
Start date: 2020-07-01
End date: 2022-06-30
Duration (months): 24.0
Total project cost (EUR): 175572.48
EU funding (EUR): 175572.48
Participants: 1
Project status: SIGNED

“Gl.EXO” is about innovative tools to detect Glioblastoma (GBM) exosomes and to have a timely, accurate and non-invasive diagnosis of GBM. Several studies have underlined the role of exosome cell–cell communication in different tumour types, including GBM, suggesting their potential use as diagnostic/prognostic/predictive biomarkers and therapeutic agents. In fact, evidences have demonstrated that the release of GBM exosomes plays a key role in cancer growth and progression by modulating tumor microenviroment and affecting angiogenesis, tumour migration, immune escape and drug resistance. However, GBM exosomes-enriched proteins characterization started only since few years and studies still lack informations on GBM exosomes cargo and their impact on cancer progression. Moreover, the identification of specific biomarkers able to discriminate between cancer exosomes from normal exosomes and tools for their detection are necessary and still unknown. Therefore, by inhibiting GBM exosomes uptake, “Gl.EXO” will contribute to hamper GBM progression in many cancer aspects. To address this issue, “Gl.EXO” aims to use nucleic acid-based aptamers as innovative tools to detect specifically GBM exosomes.

Keywords: glioblastoma,exosomes
INSULYNC: Changing the way diabetes is treated (INSULYNC)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: SME instrument
Countries involved: Iceland
Call: Open Disruptive Innovation Scheme (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2018-02-01
End date: 2018-05-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Medilync is a start-up based in Iceland and founded in 2012 with the goal of revolutionizing the management and treatment of diabetes. Medilync has created a medical device that simplifies the way patients manage glucose measurement and insulin delivery. Diabetes requires a highly-disciplined routine of glucose control and insulin injections, being lack of accuracy and of recordkeeping one of the main reasons for a deteriorating health. There are about 60 million people with diabetes in the EU and this number will rise to 71 million by 2040. Up to 75% of all people with diabetes are not in good control of their condition, leading to huge social and economic costs. 40% of diabetes patients are >65 years, and need to involve family members, friends and providers in real-time to improve adherence to treatment. Medilync brings the first all-in-one medical device, INSULYNC, which allows for easy blood glucose measuring, recording of the injection of insulin, and real-time delivery of all this information for storage on a cloud computing system, Cloudlync, sharing it with the doctor and the patient’s family. INSULYNC and Cloudlync are highly integrated to help the patient keep track of medication and to organize all data relative to diabetes management under one single system. The solution helps patients to engage with family and doctors (improves treatment adherence by 35%), with the result of patients spending less (could save around €40 billion a year to European healthcare systems) and being in better health. The overall objectives of this project include finalizing and validating INSULYNC and Cloudlync with key stakeholders (e.g. clinical trials in key target markets), and preparing our entry strategy into the European market. Through this project we aim to boost the growth of our company and obtain €14.17M revenues (overall profit of 55%), while creating 30 new jobs by 2025, with a ROI of €4.9 per euro invested.

Keywords: diabetes,type 2 diabetes,diabetes monitoring,diabetes management,glucose,wearable,device,e health,patient
Robust Actuation through Magnetism for Safe Endovascular Surgery (RAMSES)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Panel: Systems and communication engineering
Panel description: Electrical, electronic, communication, optical and systems engineering
Countries involved: Netherlands
Call: Call for proposals for ERC Proof of Concept Grant (ERC-2020-PoC, 2020)
Start date: 2021-09-01
End date: 2023-02-28
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Endovascular interventions are an established class of procedures within minimally invasive surgery (MIS). They enable the treatment of cardiovascular diseases through small incisions in the body by using flexible instruments. Conventionally, these instruments are manually operated, which restricts their precision, and limits their applicability. The magnetic actuation of instruments for endovascular interventions creates a novel and effective steering alternative. Even in deeply seated regions, magnetic flexible instruments provide clinicians with dexterity, while retaining minimal access. Thereby, they permit a range of advanced surgical tasks unattainable otherwise. Nevertheless, to be remotely actuated, such instruments rely on magnetic fields originating from outside the body. Thus, the aim of RAMSES is to develop and evaluate a clinic-ready robotic system capable of generating external fields during endovascular interventions. The RAMSES system will become an enabling technology for the clinical use of magnetic surgical instruments. It will truly revolutionize MIS, opening a new market for advanced diagnosis and treatment options. The RAMSES system will contain optimized electromagnetic actuators, located on robotic manipulators and powered by dedicated control software. The resulting versatile clinical framework will be applicable to a wide range of surgical instruments. This includes both commercially-available magnetic catheters as well as novel experimental designs. As a consequence, RAMSES will satisfy the needs of clinicians to further expand the effectiveness and availability of MIS techniques. It will provide an indispensable clinical tool for accurate and comprehensive surgical interventions in hard-to-reach locations within the human body. RAMSES aspires to turn magnetic actuation into a commercially successful technology. It involves strong industrial collaborations and a dedicated business development team in an ambitious quest to make that happen.

Keywords: electromagnetics,magnetic actuators,medical robotics,minimally invasive surgery,surgical robotics
Development of a synbiotic product to modulate the Parkinson’s disease associated microbiome (SyMPaBiome)

Framework: Horizon 2020 — Spreading excellence and widening participation
Programme: Widening participation and spreading excellence
Theme: Other Widening
Action type: Marie Skłodowska-Curie actions
Countries involved: Luxembourg
Call: Widening Fellowships (H2020-WF-03-2020, 2020)
Start date: 2022-01-01
End date: 2023-12-31
Duration (months): 24.0
Total project cost (EUR): 166320.0
EU funding (EUR): 166320.0
Participants: 1
Project status: SIGNED

SyMPaBiome aims to develop a synbiotic, a mixture of live biotherapeutic bacteria and a prebiotic, to modulate the Parkinson’s disease (PD) microbiome, with the threefold aim to decrease (1) the intestinal (neuro-)inflammation and (2) gut permeability associated with PD, as well as to (3) decrease the production of a recently discovered archaeal metabolite linked to PD development and progression. This synbiotic regimen will be the first mechanism-based synbiotic formulation, underpinned by functional read-outs from a unique gut-on-a-chip host-microbe interface model. PD is the second most common neurodegenerative disease, and remains incurable. Gastrointestinal symptoms precede the characteristic motor symptoms by years to decades and there is evidence supporting initiation of the disease by enteric inflammation and changes in microbial community composition and function. Enteric inflammation in PD is exacerbated by an increased gut permeability and mucus-foraging bacteria are more abundant in the PD microbiome, while fibre-degrading bacteria are decreased. This offers the opportunity to develop prophylactic or disease-modulating products to address these changes in at-risk individuals or PD patients. Recently, the archaeal metabolite 2-hydroxypyridone (2-HP), a co-factor of the hydrogenase in hydrogenotrophic methanogenic archaea, has been implicated in idiopathic PD aetiology. Here, a preventive or disease modulating strategy is proposed to induce a shift in the microbiome and metabolome of at-risk individuals or PD patients and decrease 2-HP production and its cytotoxic effects on the enteric nervous system. In view of this, we aim to develop a synbiotic product that can restore the metabolic profile and microbial community in PD patients and has a protective effect on the intestinal mucus and epithelium. The outcomes of this project will be a synbiotic formulation, ready for in vivo testing, and a toolbox for mechanism-based development of synbiotic products.

Keywords: host microbe interaction,probiotic,prebiotic,synbiotic,intestinal inflammation
Startup Driven Innovation in European Media (STADIEM)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Germany,Estonia,Ireland,Switzerland,Norway,Switzerland,Belgium,United Kingdom
Call: Next Generation Media (H2020-ICT-2020-1, 2020)
Start date: 2020-10-01
End date: 2023-09-30
Duration (months): 36.0
Total project cost (EUR): 5812812.31
EU funding (EUR): 5499556.12
Participants: 9
Project status: SIGNED

STADIEM’s ambition is to boost the opportunities and foster the success of European media startups by the creation and deployment of cross border, innovation to market startup growth, development and piloting program between startups, innovation Hubs and other actors. As such STADIEM aims to solve the three key pain points in European media sector: cross border scalability, startup to corporate to market tech transfer, and availability of innovative media services in a Digital Single Market framework. STADIEM intends to break barriers in Europe, fostering stronger visibility and opportunities for startups active in the media industry. The main approach is to create a powerful network of media sandboxes and accelerators that foster the development and scale-up of future media solutions, with a focus on the integration of emerging technologies such as 5G, Cloud, IoT, VR, AR and beyond, smart objects, wearables, data analytics, AI, ... Individual objectives of the project include: Setting up a cross-border community of ecosystems that brings together four innovation hubs focused on media acceleration and achieve seamless collaboration between the hubs and their ecosystems. Develop a cross-border European market-driven media-tech framework and tools focusing on innovation product to market approach including piloting of innovative services with corporate stakeholders Open Innovation matchmaking, including launching two open calls for startups to join the 4-stage programme. Create synergies with relevant activities in Europe and worldwide, with the objective to foster awareness, and to offer improved services to startups and scaleups within the network. Create a sustainable ecosystem for startups in media and creative industries. The consortium consists of 4 media innovation hubs in Europe: VRT, Media City Bergen, StoryTek and NMA; which are reinforced by 3 strong players in community building and dissemination Martel Innovate, EBU and F6S.

Keywords: media,innovation,startups,scaleups,incubation,acceleration,media sandbox,startup ecosystem creation
Recycling technology to introduce rubber from End-of-Life Tyres into production lines as virgin rubbers substitute (VALUE-RUBBER)

Framework: Horizon 2020 — Industrial Leadership
Action type: Innovation actions
Countries involved: Spain,Spain,Belgium,France,France,France
Call: Fast Track to Innovation (FTI) (H2020-EIC-FTI-2018-2020, 2019)
Start date: 2019-09-01
End date: 2022-08-31
Duration (months): 36.0
Total project cost (EUR): 2449450.5
EU funding (EUR): 1934234.1
Participants: 7
Project status: CLOSED

Since 2008, European Waste Framework Directive establishes End-of-Life Tyres (ELTs) mandatory managing. In Europe, more than 3 million ELTs tonnes are generated every year. Regarding material recovery, primary recycling treatments produce ELTs granulated rubbers. Current market R&D efforts are focused on adapt downcycling applications to these granulated rubbers, featuring an open-loop recycling, since it doesn´t recover rubber to be introduced as raw material in rubber industry. Hence, not exploiting the great potential of ELTs rubbers, leading to a non-resource efficient and less European competitiveness. VALUE-RUBBER proposes a game-changing idea, betting for the high risk innovation of fully recovering rubber from ELTs to be used as a real substitute of virgin rubbers. Consortium partners are working together in order to assure a successful development and further industrial stage of DevulCore, an innovative recycling technology of rubber from ELTs which achieves the complete rubber devulcanization. The obtained product is a recycled rubber, Value-Rubber, with a maximized potential to be used as a full substitute of virgin rubbers in conventional manufacturing processes. DevulCore technology is already demonstrated in relevant environment obtaining high quality products. The consortium business vision includes the commercialization of the DevulCore technology and the Value-Rubber products as well as the exploitation of the 1st DevulCore Plant. Our market-driven innovation will contribute to the EU circular economy and EU raw materials challenge, while it will both create a new market for ELT recyclers and fulfill demands of EU rubber goods manufacturers. It is expected an important growth for consortium companies, obtaining a total turnover above €178.24 M, a total profit of €41.56 M and a ROI of 878% in 2022-2025 period. Some expected benefits are: Savings for European end-users of €965.62 M, creation of 1,802 new jobs and 4.64 Mtonnes of CO2 savings.

Keywords: devulcanization,recycling technology,critical raw materials,end of life tyres
Biological analysis of soils and advanced data analytics for precision agriculture maps (BIOMAP2SOIL)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-12-01
End date: 2020-05-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The growth of precision agriculture is hampered by the variability of soils. Parameters such as soil texture, water content, pH or biological properties are fundamental for determining the need and use of irrigation, seeds, fertilizers or pesticides. However, current sampling and analysis techniques to characterize soils are inefficient and expensive, as they require a large number of samples. BIOMAP2SOIL is a new cost-effective sampling and analysis method, based on our deep farming knowledge and statistical models, which will generate accurate soil maps of relevant parameters, including biological properties. BIOMAP2SOIL provides recommendations for an integrated crop management related to crop selection, irrigation, pest and diseases control, variable seeding and fertilizing, while minimizing the number and cost of sampling and analysis. FARMERS will improve operations, profitability and sustainability of their crops. BIOMAP2SOIL’s recommendations for optimizing crop management will lead to impacts on yield (up to +10%), water and energy consumption (up to -12%), crop diseases (up to -20%), seeds consumption (up to -5%), fertilizers consumption (up to -10%) and pollution (up to -10%), according to our actual experiences. Economic benefits for farmers are estimated in preliminary studies for 6 crops in the range of €132 – €642 per Ha for an average service cost of €90 per Ha. BIOMAP2SOIL is currently at TRL6, and to reach a TRL9 we need to validate initial correlations achieved between soil enzymes, apparent electrical conductivity and other relevant parameters; but also refine data analytics, software design and the strategy to scale-up the model, based on deep statistics and big data analytics, as well as a network of Strategic Partners, overtaking our fragmented competition. BIOMAP2SOIL is a solution mainly addressed to farmers with irrigation crops, organic farming, high technical infrastructure and vulnerable areas of nitrate pollution.

Keywords: precision agriculture,soil mapping,biological analysis,microorganisms,pathogen agents,apparent electrical conductivity,big data analytics